Nivolumab for Relapsed or Residual Haematological Malignancies After Allogeneic Stem Cell Transplantation
NCT03146468
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
14
Enrollment
OTHER
Sponsor class
Conditions
Haematological Malignancy
Interventions
DRUG:
Nivolumab Injection
Sponsor
Melbourne Health